Kevin Dahill is a Principal of Phoenix Management Partners, a company that evaluates, acquires and manages venture capital investment portfolios originally made by others. Prior to co-founding Phoenix, Kevin was Vice President of Content Operations for divine, Incorporated, having joined divine when SageMaker Incorporated, a content delivery and management start-up, was acquired by divine in March of 2001.

Prior to divine, Kevin was Vice President, Finance and Chief Financial Officer at Mobius Management Systems, Inc., a total content management software provider. As Chief Financial Officer, Kevin was responsible for three initial public offerings: Mobius in 1998; EIS International, Inc., a systems provider to call centers, in 1993; and Iomega Corporation, a removable storage manufacturer, in 1983.

Kevin has a BS in Mechanical Engineering from Notre Dame, an MS in Mechanical Engineering from Georgia Tech, and an MS in Management from the Sloan School at MIT. He provides expertise to PhySoft in the areas of technology development, support, and product positioning. Kevin plays a large role in the financial planning of the company to ensure the resources are available to provide the foundation for continued growth and market expansion.

Daniel Einhorn is General Partner of Capital Midwest Fund. He has ten years experience, evaluating, screening, and investing in private technology companies. Daniel is on the board of LiquidCool Solutions, Rapid Diagnostek, Physician Software Systems, Always In Touch and PreEmptive Meds. He is a member of the Board of the Entrepreneur Center at Illinois Institute of Technology, and the Southern Methodist University Alumni. He is on the board of COA Youth & Family Centers and the Jewish Museum in Milwaukee. He is a member of the Midwest Health Investment Network. In 2012, he was named Man of the Year for the Milwaukee Chapter of the Leukemia and Lymphoma Society.

Daniel holds an MBA in finance from the Cox School of Business at Southern Methodist University. He plays a significant role in the company’s financial planning, as well as providing insight into trends in the healthcare technology market place.

Mayo Clinic Ventures patents Mayo Clinic inventions, licenses technologies for commercialization, and starts new companies related to Mayo Clinic’s intellectual property, all with the focus on improving patient care worldwide. Before joining Mayo Clinic Ventures, Barbara worked as a Contract Manager within Mayo Clinic’s Legal Contract Administration and an IP Analyst for IBM. Barbara received her BS degree in Paralegal Studies from Winona State University with a minor in Sociology and her MA degree in both Health and Human Service Administration and Management from Saint Mary’s University.

Barbara Keller is a Technology Licensing Manager within Mayo Clinic Ventures. Mayo Clinic Ventures is the organization dedicated to converting Mayo Clinic’s ideas, ingenuity and expertise into health care products and services.

Barbara is key to discussions and investigations into new applications for Physician Software Systems technologies and introductions to potential partners with complementary products and significant new research.

Lewie Mitchell, a Mayo Clinic Entrepreneur in Residence, has spent his more than 30-year career in high technology taking people and organizations to new levels of success. Lewie has served and led companies ranging from the Fortune 50 to pre-IPO startups in general management, as well as directly managing operations, finance, sales, marketing, product development, and professional services. Lewie has a Bachelor of Science in Electrical Engineering from the University of Illinois and an MBA from the University of Chicago.

As the architect of PhySoft’s strategic direction, Lewie has assembled technology, finance, support, sales, and marketing teams with extensive and diverse something in education, experience, and skills. Lewie has also taken the lead in building the company’s Scientific Advisory Board with professionals ideally suited to contribute to the company’s growth and success by guiding the company in adding to the capabilities of existing products and the exploration of new areas in which we may help determine optimal regimens for difficult-to-dose drugs.

Dr. Albright is an accomplished physician specializing in nephrology with a strong focus on acute and chronic kidney disease management. His expertise spans acute renal failure, covering outcomes, epidemiology, and therapy, as well as protein metabolism in renal disease and end-stage renal disease therapy. He has contributed significantly to advancing understanding of anemia management, dialysis access, and new therapeutic modalities, while also exploring the impact of acid-base disorders on kidney disease progression and outcomes.

In his clinical practice, Dr. Albright focuses on the management of acute kidney injury in critically ill patients, the treatment of kidney failure requiring dialysis, and the prevention and management of complications such as anemia and bone disease. His work emphasizes both patient-centered care and critical evaluation of quality across the continuum of chronic kidney disease treatment. By bridging clinical expertise with research-driven insight, he ensures that patients benefit from the most effective, evidence-based therapies available.

Dr. Albright holds a primary appointment in nephrology with a joint appointment in pulmonary and critical care medicine. He currently serves as Assistant Professor of Medicine at the Mayo Clinic College of Medicine and Science. In addition to his academic role, he is Vice Chair of the Division of Nephrology and Hypertension at Mayo Clinic in Rochester, Minnesota, and Medical Director of Mayo Clinic Dialysis Services, where he oversees patient care delivery and quality initiatives.

Dr. Albright’s medical training reflects a deep commitment to both nephrology and critical care. Dr. Albright completed fellowship training in nephrology and critical care medicine at the Mayo Graduate School of Medicine, Mayo Clinic, where he also completed his residency in internal medicine. He began his postgraduate training as Chief Intern at the Community Hospital of Lancaster. He earned his Doctor of Osteopathy degree from the Philadelphia College of Osteopathic Medicine and holds a Bachelor of Science in Biology from Juniata College in Huntingdon, Pennsylvania.

Through his leadership roles, teaching responsibilities, and research focus, Dr. Albright has established himself as a trusted clinician and thought leader in nephrology. His career is distinguished by a dedication to improving outcomes for patients with kidney disease, advancing therapeutic approaches, and setting high standards of quality in patient care.

Dr. Dingli is a physician, scientist, and Professor of Medicine at Mayo Clinic. He specializes in hematology, with a primary focus on the treatment of multiple myeloma and related plasma cell disorders. Many of the patients he cares for experience kidney complications as part of their disease, which further shapes his integrated approach to care. Alongside his clinical work, Dr. Dingli has built a distinguished research career centered on mathematical and computational modeling of hematopoiesis and its disorders, advancing both scientific understanding and therapeutic practice.

Dr. Dingli’s research has contributed to the development of models that describe the dynamics of blood formation and the disorders that arise in bone marrow cells. These models help elucidate how hematopoietic stem cells and progenitors behave under normal conditions and how mutations accumulate and evolve into cancers of the bone marrow. By applying concepts from evolutionary biology, Dr. Dingli has provided valuable insights into the origins and progression of blood cancers, highlighting tumor development as an evolutionary process.

A key area of his work involves developing algorithms that optimize the use of novel therapeutics, such as small molecules and tumor-selective viruses. His research supports the advancement of personalized medicine, tailoring treatment to individual patients while minimizing risks and costs. Given the high expense of many cancer therapies, Dr. Dingli’s quantitative approach to therapy design not only improves safety and efficacy but also addresses the broader economic challenges of cancer care.

In addition to his clinical and research roles, Dr. Dingli contributes extensively to the scientific community. He serves as Editor-in-Chief of Blood and Lymphatic Cancer: Targets and Therapy and sits on the editorial boards of multiple journals, including Hematology Reviews and Journal of Hematology. He is also an active scientific reviewer for major organizations such as Cancer Research UK, the Leukemia Research Fund, the National Science Foundation, and numerous peer-reviewed journals across hematology, oncology, computational biology, and applied mathematics. Widely recognized for his contributions, Dr. Dingli is the recipient of more than 30 awards, a fellow of several scientific societies, and the author of over 150 publications, abstracts, and book chapters.

Dr. Dingli’s training reflects a rare blend of medicine, mathematics, and computational sciences. He earned his M.D. with distinction from the University of Malta and completed his residency in internal medicine and fellowship in hematology at the Mayo School of Graduate Medical Education, College of Medicine, Mayo Clinic. He also holds a Ph.D. in biomedical sciences from the Mayo Graduate School and has pursued advanced training in mathematical modeling at Harvard University’s Program for Evolutionary Dynamics and the Santa Fe Institute. This unique multidisciplinary background underpins his innovative approach to both research and clinical practice, uniting medicine and mathematics to improve patient outcomes.

Stephen Gudgell is a Chief Administrative Officer for the Mayo Clinic Health System. He has spent more than 30 years at Mayo Clinic, starting as a nurse and supervisor in Intensive Care, Flight Nursing, and the Emergency Services.

Steve formerly served as Operations Administrator for the Division of Nephrology and Hypertension at Mayo Clinic and Mayo Clinic Dialysis Services, as well as Administrator for Mayo Clinic’s Department of Medicine’s outpatient practice. In all those roles, Steve actively led the clinic’s efforts to improve and standardize care. He had direct administrative responsibility for eight of Mayo Clinic’s dialysis facilities and led the operational and financial performance improvements of these units through strategic planning and process improvement techniques.

Steve was integral to the initial development of Mayo Clinic’s anemia management software tool, which simulates a patient’s response to ESAs and develops an individualized and optimum dosing regimen to improve anemia management. These efforts led to a significant reduction in ESA usage and expense and improved patient outcomes at each of the facilities.

Steve also oversaw the development of a performance dashboard for all of the facilities to track data values used to evaluate dialysis services by CMS, improving care and building a more collaborative environment for operations, staff, nursing and medical directors.

Craig Hocum is a Board Certified Physician Assistant with 32 years of experience in a variety of medical disciplines including surgery, family practice, internal medicine, ER, and primary care. Craig currently practices in the Nephrology Division of Internal Medicine at the Mayo Clinic in Rochester, Minnesota. He is Director and Manager of the Mayo Clinic Anemia Management System for approximately 660 patients within the Mayo Clinic Dialysis System. He co-manages more than 120 patients using in-center, outpatient, and home dialysis services.

Craig is a member of the International Society of System Dynamics and was an integral part of the Mayo Clinic team that developed the Mayo Clinic Anemia Management System (MCAMS). He has many years of experience as the technology’s primary user at Mayo and now utilizes that background to advise PhySoft on the intricacies of modeling dialysis patients’ response to ESAs, patient monitoring and management, and system interface design.

Craig also has a lead role on PhySoft’s enhancement committee.

Peter Ivanovich, M.D., is Attending Nephrologist at the Jesse Brown VA Medical Center and a professor of Medicine at Northwestern University Feinberg School of Medicine. He has pioneered research in dialysis, vascular access for dialysis, kidney preservation, and erythropoiesis stimulating agents.

Dr. Ivanovich is past president of the International Society for Artificial Organs and the World Apheresis Association, fellow of the Royal College of Physicians of Edinburgh, a member of the Leibniz Societaet, and the recipient of numerous national and international awards.

We regret to report that Dr. Ivanovich passed away on November 16, 2019. He was an esteemed colleague and friend to so many in the field of medicine. He will be greatly missed, especially here at PhySoft.

Dr. McCarthy is a clinical nephrologist dedicated to improving survival and quality of life for patients with chronic kidney disease, particularly those receiving chronic dialysis. His work combines patient care with clinical research aimed at identifying and addressing factors that influence outcomes for this vulnerable population. By focusing on both survival and quality of life, Dr. McCarthy has become a leader in advancing treatment strategies for kidney disease patients.

Much of Dr. McCarthy’s research involves the analysis of patient outcomes and participation in interventional trials that directly inform clinical practice. His investigations are designed to reduce hospitalizations, extend survival, and enhance overall well-being for individuals with chronic kidney disease. With nearly half a million Americans currently on dialysis or living with kidney transplants, and as many as 10 to 20 million affected by significant kidney disease, the impact of his work is far-reaching and of national importance.

His research interests include mineral metabolism in chronic kidney disease, with particular attention to phosphorus management, hyperparathyroidism, and the treatment of calciphylaxis, a severe and life-threatening disorder. He has also advanced the management of anemia in kidney disease, developing computer-based systems to guide physicians in the efficient use of iron therapies and erythropoiesis-stimulating agents. These systems help maintain safe hemoglobin levels, reduce the need for transfusions, and improve patients’ overall sense of well-being. In addition, Dr. McCarthy has focused on circulatory access for dialysis patients, working to establish best practices for the use of catheters and fistulas—critical “lifelines” for those receiving hemodialysis.

Dr. McCarthy’s leadership roles extend across Mayo Clinic and the broader nephrology community. Since 2009, he has served as Chair of the Division of Nephrology & Hypertension at Mayo Clinic in Rochester, Minnesota. He has held numerous influential positions, including membership on the Board of Directors for Mayo Clinic Health System, chairmanship of the Mayo Clinic Health System EMR Oversight Group, and leadership roles within the ESRD Network 11 Medical Review Committee and the National Forum of ESRD Networks. He has also contributed to national guideline development as a member of the National Kidney Foundation KDOQI Workgroup for Bone Disease.

Dr. McCarthy’s training laid the foundation for his distinguished career. He earned his M.D. from the University of Kansas Medical School and completed his residency in internal medicine and fellowship in nephrology at the Mayo Graduate School of Medicine, College of Medicine, Mayo Clinic. He also holds a B.A. in biochemistry, with honors, from the University of Kansas. Through his leadership, research, and clinical practice, Dr. McCarthy has made lasting contributions to nephrology, ensuring that patients with chronic kidney disease receive care that is evidence-based, effective, and focused on improving both longevity and quality of life.